Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Immunomedics Inc (IMMU)

Immunomedics Inc (IMMU)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 20,308,312
  • Shares Outstanding, K 231,144
  • Annual Sales, $ 300 K
  • Annual Income, $ -357,190 K
  • 60-Month Beta 2.90
  • Price/Sales 68,810.40
  • Price/Cash Flow N/A
  • Price/Book 34.29
Trade IMMU with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.73
  • Most Recent Earnings -0.30 on 08/05/20
  • Next Earnings Date 11/04/20
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate -0.25
  • Number of Estimates 4
  • High Estimate -0.18
  • Low Estimate -0.33
  • Prior Year -0.49
  • Growth Rate Est. (year over year) +48.98%

Price Performance

See More
Period Period Low Period High Performance
1-Month
84.84 +3.56%
on 09/30/20
87.93 -0.08%
on 10/22/20
+2.81 (+3.30%)
since 09/22/20
3-Month
37.85 +132.13%
on 09/04/20
87.93 -0.08%
on 10/22/20
+44.70 (+103.57%)
since 07/22/20
52-Week
8.80 +898.41%
on 04/03/20
87.93 -0.08%
on 10/22/20
+71.77 (+446.05%)
since 10/22/19

Most Recent Stories

More News
Portnoy Law Firm: Tactile Systems Technology, Inc., Pintec Technologies Holdings Limited, and Immunomedics, Inc. Investors Have Limited Amount of Time Before Class Action Deadline

The Portnoy Law Firm advises investors that class action lawsuits have been filed on behalf of investors in the following publicly traded companies. Shareholders interested in taking an active role in...

TCMD : 43.11 (+1.17%)
PT : 0.9900 (-5.71%)
IMMU : 87.86 (+0.05%)
Processa Pharmaceuticals Announces the Appointment of Dr. Khalid Islam to Its Board of Directors

Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), ("Processa" or the "Company"), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients...

PCSA : 6.35 (+8.92%)
FENC : 7.82 (+1.03%)
IMMU : 87.86 (+0.05%)
Gilead Sciences Completes Acquisition of Immunomedics, Inc.

Gilead Sciences, Inc. (Nasdaq: GILD) today announced the completion of the previously announced transaction to acquire Immunomedics, Inc. (Nasdaq: IMMU) for approximately $21 billion in the aggregate.

GILD : 60.67 (+1.07%)
IMMU : 87.86 (+0.05%)
Will Coronavirus Woes Affect Gilead's (GILD) Q3 Earnings?

Investors will focus on the HIV franchise's performance and the uptake of Yescarta along with updates on experimental coronavirus treatment, when Gilead (GILD) reports third-quarter 2020 results.

GILD : 60.67 (+1.07%)
IMMU : 87.86 (+0.05%)
VRTX : 227.75 (+0.46%)
HZNP : 70.43 (-0.17%)
ProteoNic Announces Licensing of Technology for Production of Biologics to Immunomedics

LEIDEN, , /PRNewswire/ -- ProteoNic BV, a leading provider of technology and services in the field of production of biologics, today announced it has licensed its premium 2G UNic™ technology for boosting...

IMMU : 87.86 (+0.05%)
4 Top Biotech Stocks to Buy for the Remainder of 2020

With huge investments being made in biotech thanks to the pandemic, there has been a renewed focus on biotech stocks. Here are four worth considering: Amgen (AMGN), Immunomedics (IMMU), Seattle Genetics...

AMGN : 222.04 (-1.23%)
SGEN : 170.31 (+0.70%)
GMAB : 38.61 (+3.99%)
IMMU : 87.86 (+0.05%)
Seagen Posts Upbeat Top-Line Data From EV-201 Study on Padcev

Seagen (SGEN) and partner Astellas Pharma post favorable top-line results from the second cohort of the phase II EV-201 study on Padcev to treat advanced or metastatic urothelial cancer. Stock rises.

MRK : 80.39 (+0.66%)
IMMU : 87.86 (+0.05%)
AVEO : 5.38 (-0.55%)
SGEN : 170.31 (+0.70%)
Immunomedics' Trodelvy Gets Orphan Drug Tag for Glioblastoma

Immunomedics' (IMMU) lead product candidate, Trodelvy, gets FDA orphan drug status for the treatment of adult and pediatric patients with glioblastoma.

IMMU : 87.86 (+0.05%)
AVEO : 5.38 (-0.55%)
EBS : 81.93 (-1.09%)
CSTL : 47.56 (+6.95%)
Axovant's Gene Therapy Gets Rare Pediatric Disease Status

The FDA bestows a Rare Pediatric Disease status on Axovant's (AXGT) gene therapy candidate AXO-AAV-GM1, which is being developed for the treatment of GM1 gangliosidosis. Stock appreciates.

IMMU : 87.86 (+0.05%)
AVEO : 5.38 (-0.55%)
FOLD : 22.89 (-1.51%)
AXGT : 2.10 (-2.33%)
Immunomedics Announces FDA Orphan Drug Designation of Trodelvy(TM) for Adult and Pediatric Glioblastoma

Immunomedics, Inc. (NASDAQ: IMMU) ("Immunomedics" or the "Company"), a leading biopharmaceutical company in the area of antibody-drug conjugates, today announced that the Office of Orphan Products Development...

IMMU : 87.86 (+0.05%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Business Summary

Immunomedics Inc. is a New Jersey-based biopharmaceutical company focused on the development of monoclonal, antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases. They have developed a number of advanced proprietary technologies that allow us to create humanized...

See More

Key Turning Points

2nd Resistance Point 88.13
1st Resistance Point 88.00
Last Price 87.86
1st Support Level 87.66
2nd Support Level 87.45

See More

52-Week High 87.93
Last Price 87.86
Fibonacci 61.8% 57.70
Fibonacci 50% 48.37
Fibonacci 38.2% 39.03
52-Week Low 8.80

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar